Answer
Ixekizumab is an IgG4 monoclonal antibody that binds to and neutralises interleukin‑17A, inhibiting its effects on skin-cell proliferation and activation and inflammation involved in psoriasis, psoriatic arthritis and axial spondyloarthritis.
Sources for this answer
- Taltz 80 mg solution for injection in pre-filled penEli Lilly and Company Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 18Document updated
Sources checked